

Success of trabeculectomy surgery in relation to cataract surgery: 5 year outcomes

Journal:	<i>British Journal of Ophthalmology</i>
Manuscript ID	bjophthalmol-2018-312972
Article Type:	Clinical science
Date Submitted by the Author:	30-Jul-2018
Complete List of Authors:	Mathew, Rashmi; Moorfields Eye Hospital NHS Foundation Trust, Department of glaucoma Parvizi, Sahar; Moorfields Eye Hospital NHS Foundation Trust Murdoch, Ian; The Institute of Ophthalmology, Genetics; Moorfields Eye Hospital,
Keywords:	Glaucoma, Treatment Surgery, Wound healing

SCHOLARONE™
Manuscripts

Review Only

1
2
3 **Title: Success of trabeculectomy surgery in relation to cataract**
4 **surgery: 5 year outcomes**
5
6

7 *Authors*

8 1) Ms Rashmi G Mathew, FRCOphth (corresponding author)
9
10 *Consultant Ophthalmologist, Department of Glaucoma,*
11 *Deputy Director for Undergraduate Education,*
12 *Moorfields Eye Hospital NHSFT, London, EC1v 2PD*
13 *Email: Rashmi.mathew@moorfields.nhs.uk*
14 *Tel: 020 7566 2625*
15
16
17

18
19 2) Ms Sahar Parvizi, FRCOphth
20 *Paediatrics Fellow*
21 *Moorfields Eye Hospital NHSFT, London, UK, EC1V 2PD*
22
23

24 3) Mr Ian E Murdoch, MD, FRCOphth
25 *Consultant Ophthalmologist and Senior Lecturer,*
26 *Department Epidemiology and International Eye Health*
27 *Institute of Ophthalmology, Genetics*
28 *11-43 Bath Street*
29 *London, EC1V 9EL*
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 **Synopsis**

7 Trabeculectomy success at 5 years was similar, in eyes which had trabeculectomy alone,
8 cataract surgery and then trabeculectomy any time afterwards, and trabeculectomy
9 with cataract surgery performed within two years of trabeculectomy.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

Abstract:

Aims: To compare success proportions at five years in three surgical groups:

Group 1: Trabeculectomy alone

Group 2: Trabeculectomy followed by cataract surgery within 2 years

Group 3: Trabeculectomy performed on a pseudophakic eye

Methods: A retrospective cohort study. 194 eyes of 194 patients were identified with at least 5-years follow-up post-trabeculectomy (N = 85, 60, 49 in groups 1, 2, 3 respectively).

Main Outcome Measures:

- Primary Outcome Measure: intraocular pressure (IOP) at 5 years post trabeculectomy surgery
- Secondary Outcome Measure: change in visual acuity at 5 years

Results:

At 5 years, the mean IOP (SD) was 12.9 (3.5), 12.5 (4.8), 12.7 (4.8) mmHg in groups 1,2,3 respectively. Overall success was almost identical, 58%, 57%, 59%, in groups 1,2,3 respectively. There was no significant difference between the groups in terms of percentage IOP reduction, number of medications, proportion re-starting medication, re-operation rates at 5 years. Logistic regression for an outcome of failure, showed males to be at increased risk of failure OR 1.97 (95% CI; 1.10-3.52, p=0.02).

Conclusions:

The sequence in which surgery is carried out does not appear to affect trabeculectomy function at 5 years, success being similar to trabeculectomy alone. In our study males may be at increased risk of failure.

Introduction:

Cataract and glaucoma are the two most common causes of preventable blindness in the world.¹ Both are age related, hence often coexist.² Treatment of cataract is surgical whereas therapy for glaucoma may be medical, laser or surgical. Trabeculectomy remains the most commonly considered surgical option to lower the intraocular pressure (IOP).^{3,4} One third of patients with trabeculectomy require cataract surgery within 2 years.^{5,6} This rises to two thirds by 8 years.⁷ The question about surgical order of the two procedures is widely debated in glaucoma circles. In terms of trabeculectomy survival should cataract surgery be undertaken prior to or after trabeculectomy?

Success rates of trabeculectomy surgery are difficult to sensibly interpret between studies due to differing study methods and definitions of success and failure. A 'broad brush' view of the literature is given below.

Trabeculectomy

The large audit by Kirwan et al reports success (IOP \leq 18mmHg *and* 20% reduction) at two years as 78% complete and 86% qualified success (N=428 eyes).⁵ Quigley et al using the same success criteria at 4 years reported 53% complete and 72% qualified success (N=150 eyes).⁸

Cataract surgery after trabeculectomy

In the audit by Kirwan et al 115/376 phakic eyes underwent cataract surgery during the two years post trabeculectomy period. 90/115 (78%) were complete and 99 (86%) partial success at 2 years post trabeculectomy surgery.⁵ Whilst not long follow-up after the cataract surgery this does imply little effect on the success of the trabeculectomy surgery (comparing to those with no cataract surgery $\text{Chi}^2 = 0.002$ $p=0.96$).

Looking at an outcome two years following cataract surgery the literature reports between 10-35% of functional trabeculectomies failing within this period.⁹⁻¹⁷

A few studies have looked at the effect of timing of cataract surgery on the success of trabeculectomy surgery. A declining risk has been implicated with longer intervals between the two operations.^{9,16}

Cataract surgery before trabeculectomy

Nguyen et al reported a study comparing trabeculectomy outcomes in patients with prior cataract surgery to those undergoing cataract surgery post trabeculectomy.¹⁸ All phacoemulsifications were done within one year of the trabeculectomy surgery hence it makes most sense to look at their two year results post trabeculectomy in the two groups. No difference in failure was suggested between the groups (8/30 phacoemulsification then trabeculectomy vs 7/18 trabeculectomy then phacoemulsification failed $p=0.522$).

1
2
3 Considerable debate concerning timing of the two operations continues.
4 With a view to informing future research in this area we undertook a retrospective
5 cohort study to compare trabeculectomy success at 5 years, in eyes which had
6 trabeculectomy alone, cataract surgery and then trabeculectomy at any time afterwards,
7 and trabeculectomy with cataract surgery performed afterwards within two years of
8 the trabeculectomy.
9

10 **Methods:**

11
12
13 We reviewed medical records of cases that had undergone trabeculectomy surgery and
14 had at least five years post-trabeculectomy follow-up. Eyes with acute angle closure,
15 juvenile / congenital glaucoma and rubeotic glaucoma were excluded. Those with any
16 previous intraocular surgery other than cataract surgery (e.g. vitreoretinal, glaucoma,
17 cornea, trauma, as well as phaco-trabeculectomy) were also excluded.
18

19
20 If both eyes of one individual were eligible then the eye with the more recent
21 trabeculectomy was chosen for inclusion. Cases were divided into 3 groups (figure 1):
22

- 23 • Group 1: Trabeculectomy with no cataract surgery
- 24 • Group 2: Trabeculectomy followed by cataract surgery within 2 years of the
25 trabeculectomy (cataract after trabeculectomy)
- 26 • Group 3: Trabeculectomy performed on a pseudophakic eye (the cataract surgery
27 could have been performed at any time prior to the trabeculectomy; cataract before
28 trabeculectomy)
29

30
31 The primary outcome was trabeculectomy success at five years. The definitions of
32 complete success, qualified success and failure are given below:
33

34 **Complete success:** a 20% reduction of intraocular pressure (IOP) *and* IOP ≤ 18 mmHg
35 without the need for IOP lowering therapy or further surgery at 5 years post
36 trabeculectomy.
37

38 **Qualified success:** a 20% reduction of IOP *and* IOP ≤ 18 mmHg with topical intraocular
39 pressure lowering treatment alone.
40

41
42 **Failure:** IOP not reduced by 20% *or* IOP > 18 mmHg with topical therapy *and/or* a need
43 for reoperation including a revision for clinically significant hypotony, redo
44 trabeculectomy, aqueous shunt surgery, or cyclodiode ciliary body ablation undertaken
45 within 5 years of the original trabeculectomy.
46

47
48 Bleb needling and post-operative subconjunctival injections of steroid and/or 5-
49 fluorouracil were considered part of normal post-operative care.
50

51 The secondary outcome measure was change in visual acuity, defined as a change by
52 two or more lines of vision on a Snellen chart at 5 years post trabeculectomy as
53 compared to baseline acuity.
54

55 **Sample size**

Considering the exposure of cataract surgery, a sample size of 79 unexposed (group 1) and 40 exposed (group 2 or group 3) would show a reduction in success proportion from 80% to 55% with 95% confidence and 80% power (Fleiss calculation Epi-Info v7).

Data analysis

Data was collected on a standardised proforma (Microsoft Excel spreadsheet) The outcomes of visual acuity and intraocular pressure were recorded at multiple time points.

In addition data was collected on age, gender, laterality, previous ocular history, diagnosis, new ocular pathology, number and time on topical ocular hypotensive drops, laser therapy, surgical details, operative complications, duration of post-operative topical steroid use, bleb needling procedures and further surgery.

Data was analysed using both istata v7.0 for Windows (<http://www.stata.com>) and GraphPad Prism Version 6.0d (GraphPad Software, Inc). Contingency tables were assessed for symmetry using Chi squared analysis, and continuous variables compared using a two tailed t-test. Logistic regression was undertaken investigating risk factors for the primary outcome. A p-value of less than 0.05 was considered statistically significant.

The study was approved by the Clinical Audit unit, research and development department at Moorfields Eye Hospital. Analyses of this type do not require individual ethical permission as they are viewed as audit (see <http://www.hra.nhs.uk/research-community/before-you-apply/determine-whether-your-study-is-research/>). The study was conducted in accordance with the Declaration of Helsinki, and the UK Data Protection Act.

Results:

A total number of 194 eyes (102 right) of 194 patients (92 female) were included. The baseline demographic details are shown in table 1.

	Trabeculectomy alone Group 1 n=85	Cataract after trabeculectomy Group 2 n=60	Cataract before trabeculectomy Group 3 n=49
<i>Age in years at trabeculectomy surgery mean(SD) range</i>	63.0 (SD14.4) (22 to 91)	64.2 (SD 13.1) (12 to 87)	*70.5 (SD 8.8) (48 to 87)
<i>Gender Female (%) Chi-2 =2.02 P=0.37</i>	44 (52%)	24 (40%)	24 (49%)
<i>Diagnosis</i>			
<i>POAG</i>	60 (71%)	38 (63%)	33 (67%)
<i>PXF</i>	6 (7%)	7 (12%)	6 (12%)
<i>PDG</i>	3 (4%)	2 (3%)	1 (2%)
<i>OHT</i>	2 (2%)	2 (3%)	2 (4%)
<i>Uveitic</i>	10 (12%)	9 (15%)	6 (12%)
<i>Other</i>	4 (5%)	2 (3%)	1 (2%)

Mean IOP (mmHg)SD	23.4 (8.7)	24.4 (9.8)	24.2 (8.0)
Mean number of medications	2.71	2.62	2.78
Time on medicines prior to trabeculectomy in years (n=77;57;46) mean (SD) (range)	11.1 (SD 8.0) (0 to 33)	+6.8 (SD 5.7) (0 to 21.7)	11.1 (SD 6.1) (0.5 to 27.4)

Table 1. Baseline demographic details. POAG: primary open angle glaucoma; PXF: pseudoexfoliative glaucoma; PDG: pigment dispersion glaucoma; OHT: ocular hypertension.

**t*-test significant difference Group 3 vs Group 1 ($P=0.0006$); Group 3 vs Group 2 ($P=0.005$) + *t*-test Group 2 vs Group 3 $P=0.001$; Group 2 vs Group 1 $P=0.002$

Group 3 were significantly older than groups 1 and 2; *t*-test Group 3 vs Group 1 ($P=0.0006$); Group 3 vs Group 2 ($P=0.005$). Patients were on topical and/or oral IOP lowering treatment for an average of 11 years before having trabeculectomy surgery in groups 1 and 3. Those who had had cataract surgery after trabeculectomy were on medical therapy for an average of 7 years, which is significantly less, when compared to the other two groups (*t*-test comparing group 2 with Group 1 $p<0.001$ and Group 3 $p<0.001$).

The findings by group are shown in Table 2. The mean IOP reduced from 23.4, 24.4, 24.2mmHg to 12.9, 12.5, 12.7mmHg in groups 1, 2 and 3 respectively at 5 years. The overall success was 58%, 57% and 59% in groups 1, 2, 3 respectively. The mean number of medications reduced from 2.71, 2.62, 2.78 to 1.0, 1.4 and 1.3 across the 3 groups. There was no difference in the proportion of patients restarting medication, undergoing repeat surgery for insufficient IOP control or hypotony between the groups.

	Trabeculectomy alone Group 1 n=85	Cataract after trabeculectomy Group 2 n=60	Cataract before trabeculectomy Group 3 n=49
Mean IOP (mmHg)	12.9 (SD 3.5)	12.5 (SD 4.8)	12.7 (SD 4.8)
Percent IOP change at 5 years compared to pretrabeculectomy mean IOP% change (SD) (range)	-38.8% (SD 24.7) (36 to -80%)	-41.4% (SD 31.8) (60 to -88.9%)	-43.3% (SD 24.7) (29 to -92%)
Complete success ($\geq 20\%$ IOP drop and IOP ≤ 18 mmHg)	33 (39%)	24 (40%)	21 (43%)
Qualified success ($\geq 20\%$ IOP drop on medication + IOP)	16 (19%)	10 (17%)	8 (16%)

$\leq 18\text{mmHg}$			
Failure (need for reop and/or <20% IOP drop and/or IOP >18mmHg)	36 (42%)	26 (43%)	20 (41%)
Overall success N (% (95% CI)) $\text{Chi}^2=0.1$ $p=0.97$	49 (58(47-68)%)	34 (57(44-68)%)	29 (59(45-72)%)
Mean number of medications	1.0	1.4	1.3
Medication restarting within five years Chi^2 0.17 $p=0.92$	37 (44%)	26 (43%)	19 (40%)
Repeat IOP lowering procedure within five years	10 (12%)	10 (17%)	10 (20%)
Repeat surgery for hypotony/bleb leak within five years	6 (7%)	3 (5%)	3 (6%)
Needling of bleb within five years	7 (8%)	3 (5%)	2 (4%)

Table 2. Outcomes for each surgical group at 5 years. No results showed a statistical difference between groups.

Logistic regression was undertaken for an outcome of failure (see table3). Failure definition being, IOP not reduced by 20% or IOP > 18mmHg with topical therapy and/or a need for reoperation including a revision for clinically significant hypotony, redo trabeculectomy, aqueous shunt surgery, or cyclodiode ciliary body ablation undertaken within 5 years of the original trabeculectomy). The results do not suggest major confounding and mirror the results of the contingency tables. There was a gender difference, male patients being more at risk of failure (multivariate OR 1.95 $p=0.04$). In view of the possibility of early differences we examined outcomes at each yearly interval and there was no pattern of more rapid failure in any one particular group.

Risk factor	Univariate OR (95% CI,p)	Multivariate OR (95% CI,p)
Age at trabeculectomy	0.985 (0.964-1.007, $p=0.190$)	0.989 (0.963-1.015, $p=0.396$)
Gender 0=female 1=male	1.968 (1.101-3.518, $p=0.022$)	1.950 (1.043-3.646, $p=0.037$)
Diagnosis 0=POAG/OHT	0.727 (0.385-1.371, $p=0.325$)	0.923 (0.463-1.843, $p=0.821$)

1=secondary glaucoma		
Cataract surgery 0=trabeculectomy alone 1=cataract before trabeculectomy 2=cataract after trabeculectomy	1.017 (0.729-1.418, p=0.923)	
Cataract surgery 0=trabeculectomy alone 1= cataract + trabeculectomy	0.994 (0.560-1.765, p=0.983)	1.089 (0.573-2.069, p=0.796)
Cytotoxic use 0=none (n=0) 1=5-fluorouracil (n=15) 2= mitomycin C(n=143) Unknown = 36	0.875(0.301-2.543, p=0.806)	
Time on meds before surgery 0=less than 1 year 1=1-5 years 2=5-15 years 3=15+ years	0.904 (0.655-1.248, p=0.541)	0.945 (0.659-1.356), p=0.759
Time to phaco post trabeculectomy	1.002 (0.998-1.005, p=0.317)	

Table 3. Logistic regression for an outcome of failure of trabeculectomy at 5 years.

Cataract surgery following trabeculectomy was complicated by vitreous loss in 3 cases two of which failed and the remaining case was a partial success at 5 years. Both the mean and median time to cataract surgery after trabeculectomy was 1.2 years (range 0.3-2.0; SD 0.5 years). Seventeen had 5-FU used at the time of cataract surgery or in the immediate post-operative period. There was no statistical difference in overall success between those with and without cytotoxic use ($\text{Chi}^2 = 2.54$ $p=0.11$).

The secondary outcome measure of visual acuity change at 5 years post-trabeculectomy, showed nearly 80% of patients retained or improved their vision following their initial trabeculectomy. Table 4 illustrates the visual acuity changes of two Snellen lines or more at 5 years compared to pre-trabeculectomy acuities within each group. The visual acuity was significantly better in group 2 at years and overall $\text{Chi}^2 = 20.6$, $p=0.0004$. It should be noted that Group 3 were a significantly older group, with more ocular co-morbidity.

	Trabeculectomy alone (n=83)	Cataract surgery within 2 years of trabeculectomy (n=60)	Cataract surgery before trabeculectomy (n=49)
VA worse $\text{Chi}^2=7.26$ $p=0.26$ (n=38)	20.5% (17/83)	10.0% (6/60)	30.6% (15/49)
VA same $\text{Chi}^2=2.53$ $p=0.28$ (n=145)	79.5% (66/83)	76.7% (46/60)	67.4% (33/49)

VA better $Chi^2=14.9$ $p=0.006$ ($n=9$)	0% (0/83)	13.3% (8/60)	2.0% (1/49)
Lines of change in VA at 5 years compared to pretrabeculectomy mean line change (SD)(range)	-0.9 (SD 2.0) (-9 to 1)	-0.1 (SD 2.4) (-9 to 6)	-1.1 (SD 2.1) (-8 to 2)

Table 4. Secondary outcomes measure of change in visual acuity at year 5 after trabeculectomy surgery as compared to baseline. At least two lines of vision (Snellen) gained or lost was used to define 'better' and 'worse' respectively.

Discussion:

We report a retrospective cohort study comparing trabeculectomy success at 5 years, in eyes which had trabeculectomy alone, cataract surgery and then trabeculectomy at any time afterwards, and trabeculectomy with cataract surgery performed afterwards within two years of the trabeculectomy. Our findings have not suggested any major difference between the three groups.

The overall success proportion for our combined data at five years was 58% (95% CI 51-65%). This is lower than those reported by Jampel et al and the Singapore 5 FU trial.^{8,7} Jampel et al found 72% (95% CI 66-78%) at 4 years for the same outcome definition.⁸ It could be that the extra year of follow-up in our study, accounts for some additional attrition in success proportion. In the Singapore study an overall success proportion of 73% (95% CI 66-79%) was found at 8 years, this study had the same IOP cut-off however did not include the 20% reduction criterion.⁷ The complete success proportion was similar to our study 45% (95% CI 37 -55%). Another explanation for the lower success proportion in our study could be an element of selective bias in our sample. Failing trabeculectomies are more likely to have frequent review. Their notes might therefore be more readily accessible for study inclusion.

As outlined in the introduction, the literature reports variable findings with ordering of cataract and trabeculectomy surgery. There is a prevalent clinical impression that subsequent cataract surgery negatively impacts on trabeculectomy survival. Our finding of no difference in failure proportions between trabeculectomy and trabeculectomy followed by cataract extraction is in agreement with the other reports in the literature. The Singapore 5FU trial reported no difference between those with functional trabeculectomies and subsequent cataract surgery (failure 22% (95%CI 15-32%) at median 5 years) and those with no cataract surgery (failure 27% (95%CI 20-36%) at median 5 years).⁹ Ehnrooth et al reported a higher failure proportion in those with subsequent cataract surgery, however they included trabeculectomies that had failed prior to the cataract surgery.¹¹ If those are excluded from the analysis the difference becomes smaller; functional trabeculectomies and subsequent cataract surgery (failure 44% (95%CI 28-61%)) and those with no cataract surgery (failure 31% (95%CI 22-41%)). Swamynathan et al reported no major difference in success proportions between trabeculectomy and trabeculectomy followed by cataract extraction.¹²

Clinicians generally believe that if cataract surgery is necessary it impacts less on trabeculectomy survival if undertaken first. Our finding of no difference in failure proportions whether cataract surgery is undertaken before or after trabeculectomy is in

1
2
3 agreement with the findings reported by Nguyen et al.¹⁸ They found trabeculectomy
4 followed by cataract extraction (failure 39% (95% CI 20-61%)) and cataract surgery
5 followed by trabeculectomy surgery (failure 27% (95% CI 14-45%)).
6

7 Alternative reasons for our finding of no difference could include:
8

- 9 ○ Age – group 3 were significantly older. If prior cataract surgery was a risk factor
10 for failure and increasing age a protective factor for failure of subsequent
11 trabeculectomy this might explain a negative finding. The logistic regression
12 however, did not suggest this to be the case.
- 13 ○ Gender – male gender was found to be a risk factor for failure. Other studies have
14 not found this association and we do not have an explanation. One possible
15 reason might be compliance, but this was not assessed.
- 16 ○ Time on medications prior to surgery has been reported as a risk factor for
17 failure although not as powerful as cumulative years of therapy.¹⁹ We did not
18 collect data on cumulative years of therapy. Group 2 had a significantly shorter
19 duration on topical therapy prior to trabeculectomy surgery. This might have
20 been protective against failure and masked an adverse effect of cataract surgery
21 following trabeculectomy. The multivariate modelling however did not suggest
22 this to be the case.
- 23 ○ It has previously been reported that timing of cataract surgery after
24 trabeculectomy has an effect on trabeculectomy function; longer duration
25 between the surgeries being protective.^{9,16} Our analysis did not suggest this.
26 Hussain et al advocated the use of a reciprocal of the time to cataract surgery
27 post-trabeculectomy for investigation of time relationship to failure.⁹ We
28 undertook this analysis assigning a value of 0 to the trabeculectomy only group
29 and excluding the cataract surgery prior to trabeculectomy group. This did not
30 show any time relationship $p=0.874$. To match this paper, we also looked at
31 those with cataract surgery ≤ 6 months, 6-12 months and >12 months post
32 trabeculectomy. 1/3, 9/15 and 24/42 failed respectively ($\text{Chi}^2 = 0.737$, $p=0.692$).
33
34
35
36
37

38 Of the 3 cases with vitreous loss in Group 2, 2 had failed at 5 years, and 1 case was a
39 partial success. The finding that vitreous loss has an adverse effect on outcome is well
40 reported.^{16,20}
41

42 The merit of perioperative cytotoxic use in cataract surgery following trabeculectomy is
43 uncertain. Shahid and Salmon found no benefit of 5FU given post-operatively.²¹ Sharma
44 found a beneficial effect from perioperative 5FU at the time of cataract surgery.²² Both
45 studies had relatively small numbers. In our study the 5FU was administered at the time
46 of cataract surgery but was found to have no effect. An explanation might be case
47 selection bias for the use of 5-FU. If used in those cases felt most likely to fail, any
48 positive effect might be masked.
49
50

51 The secondary outcome measure of visual acuity change at 5 years post-
52 trabeculectomy, showed nearly 80% of patients retained or improved their vision
53 following their initial trabeculectomy. Unsurprisingly a greater proportion of Group 2
54 had improved vision over the five years following trabeculectomy surgery. Over this
55 time period the order of worsening vision was; group 2 < group 1 < group 3. An
56
57
58
59
60

1
2
3 explanation for group 1 being worse than group 2 may be cataract progression post
4 trabeculectomy.² With respect to the worst acuity in group 3, these were an older group
5 with known greater ocular co-morbidity.
6

7 **Study limitations**

8
9 There are two potential limitations to this pilot study. Firstly, as a retrospective study
10 there is potential for unquantifiable bias. For example the most accessible notes may be
11 more biased towards failures (both IOP and visual) which would be seen more
12 frequently in the clinics. However such bias would apply to all groups hence be non-
13 selective. Secondly our study sample size is powered to detect a large effect in terms of
14 difference in failure proportions. A question then arises as to the clinical importance of
15 finding a smaller effect.
16
17

18 **Conclusions**

19
20 Cataract and glaucoma often co-exist and their surgical management can be challenging.
21 This study looks at the impact of cataract surgery on trabeculectomy function and
22 whether the order of surgery affects trabeculectomy survival. We found no difference in
23 trabeculectomy survival between the 3 comparator groups at 5 years.
24 This is in broad agreement with the available literature on this topic.
25
26
27

28 **Acknowledgments:**

29
30
31 We would like to thank Sally Ameen and Naomi Tan for their contribution to case note
32 identification and Lin Lu for her contribution to data entry.
33
34

35 **References**

- 36
37
38 1) (<http://www.who.int/blindness/causes/en/>)
39 2) Mathew RG, Murdoch IE. The silent enemy: a review of cataract in relation to
40 glaucoma and trabeculectomy surgery. Br J Ophthalmol 2011; 95:1350-4.
41 3) Watson PG & Grierson I. The place of trabeculectomy in the treatment of glaucoma.
42 Ophthalmology 1981;88: 175–196.
43 4) Keenan TDL, Salmon JF, Yeates D et al. Trends in rates of trabeculectomy in England.
44 Eye 2009; 23: 1141–1149.
45 5) Kirwan JF, Lockwood AJ, Shah P et al. Trabeculectomy in the 21st century: a
46 multicenter analysis. Ophthalmology (2013) 120: 2532–2539.
47 6) Gaskin JCF, Sandhu SS, Walland MJ. Victorian trabeculectomy audit. Clin Experiment
48 Ophthalmol. 2017;45:695-700.
49 7) Wong MHY, Husain R, Ang BCH et al. The Singapore 5-fluorouracil trial. Intraocular
50 pressure outcomes at 8 years. Ophthalmology 2013;120:1127-1134.
51 8) Jampel HD, Solus JF, Tracey PA et al. Outcomes and bleb-related complications of
52 trabeculectomy. Ophthalmology 2012;119:712-722.
53 9) Husain R, Liang S, Foster PJ, et al. Cataract Surgery After Trabeculectomy: The
54 Effect on Trabeculectomy Function. Arch Ophthalmol. 2012;130:165-170.
55
56
57
58
59
60

- 10) Wong TT, Khaw PT, Aung T, et al. The Singapore 5-fluorouracil trabeculectomy study: effect on intraocular pressure control and disease progression at 3 years. *Ophthalmology* 2009;116:175-184
- 11) Ehnrooth P, Lehto I, Puska P, et al. Phacoemulsificationemulsification in trabeculectomized eyes. *Acta Ophthalmol Scand* 2005;83:561-566.
- 12) Swamynathan K, Capistrano AP, Cantor LB, et al. Effect of temporal corneal phacoemulsificationemulsification on intraocular pressure in eyes with prior trabeculectomy with an antimetabolite. *Ophthalmology* 2004;111:674-678.
- 13) Rebolleda G, Munoz-Negrete FJ. Phacoemulsificationemulsification in eyes with functioning filtering blebs: a prospective study. *Ophthalmology* 2002;109:2248-55
- 14) Casson RJ, Riddell CE, Rahman R, et al. Long-term effect of cataract surgery on intraocular pressure after trabeculectomy. Extracapsular extraction versus phacoemulsificationemulsification. *J Cataract Refract Surg* 2002;28:2159-64.
- 15) Crichton AC, Kirker AW. Intraocular pressure and medication control after clear corneal phacoemulsificationemulsification and AcrySof posterior chamber intraocular lens implantation in patients with filtering blebs. *J Glaucoma* 2001;10:38-46
- 16) Chen PP, Weaver YK, Budenz DL, et al. Trabeculectomy function after cataract extraction. *Ophthalmology* 1998; 105:1928-35
- 17) Park HJ, Kwon YH, Weitzman M, et al. Temporal corneal phacoemulsificationemulsification in patients with filtered glaucoma. *Arch Ophthalmol* 1997;115:1375-1380
- 18) Nguyen DQ, Niyadurupola N, Tapp RJ, O'Connell RA, Coote MA, Crowston JG. Effect of phacoemulsificationemulsification on trabeculectomy function. *Clin Experiment Ophthalmol*. 2014;42:433-439.
- 19) Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. *Br J Ophthalmol* 1993;77:590-596
- 20) Seah SK, Jap A, Prata, JA Jr et al. Cataract Surgery After Trabeculectomy. *Ophthalmic Surgery and Lasers* 1996;27:587-94.
- 21) Shahid H, Salmon JF. Use of 5-Fluorouracil injections to reduce the risk of trabeculectomy bleb failure after cataract surgery. *J Ocul Pharmacol Ther*. 2010;26:119-23
- 22) Sharma TK, Arora S, Corridan PG. Phacoemulsification in patients with previous trabeculectomy: role of 5-fluorouracil. *Eye* 2007;21:780-878.

Figure 1. Outline of the three study groups and the timing of cataract surgery, in relation to trabeculectomy surgery.

